4B6L

Discovery of Oral Polo-Like Kinase (PLK) Inhibitors with Enhanced Selectivity Profile using Residue Targeted Drug Design

Summary for 4B6L

• Entry DOI: 10.2210/pdb4b6l/pdb
• Descriptor: SERINE/THREONINE-PROTEIN KINASE PLK3, 4-[[(4R)-5-cyclopentyl-4-ethyl-3a,4-dihydro-3H-[1,2,4]triazolo[4,3-f]pteridin-7-yl]amino]-N-cyclopropyl-3-methoxy-benzamide, SULFATE ION, ... (4 entities in total)
• Functional Keywords: transferase, kinase inhibitors, water-mediated h-bond
• Biological source: HOMO SAPIENS (HUMAN)
• Cellular location: Cytoplasm: Q9H4B4
• Total number of polymer chains: 1
• Total formula weight: 32790.87

Authors

Brown, K.,Charrier, J.D.,Durrant, S.,Griffiths, M.,Hudson, C.,Kay, D.,Knegtel, R.,ODonnell, M.,Pierard, F.,Twin, H.,Weber, P.,Young, S. (deposition date: 2012-08-14, release date: 2013-08-21, Last modification date: 2024-05-08)

• Primary citation: Brown, K.,Charrier, J.D.,Durrant, S.,Griffiths, M.,Hudson, C.,Kay, D.,Knegtel, R.,Odonnell, M.,Pierard, F.,Twin, H.,Weber, P.,Young, S.; Discovery of Oral Polo-Like Kinase (Plk) Inhibitors with Enhanced Selectivity Profile Using Residue Targeted Drug Design; To be Published,

Experimental method

X-RAY DIFFRACTION (1.9 Å)